Stay updated with breaking news from Recognify Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive
RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile Changes in quantitative electroencephalogram (qEEG) were consistent with the results of a previous Phase 1 trial
Investegate announcements from atai Life Sciences, atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters’ over-allotment- -Received...
Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offer...